Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | KCNA5 | P22460 | 3/20 | 0.50 |
| ▸ | DRD2 | P14416 | 2/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6077954 | 0.90 | KCNH2 (0.47) | KCNH2ALDH1A1KDM4E | |
| SCHEMBL6076762 | 0.90 | KCNA5 (0.51) | KMT2AMEN1KCNA5ALDH1A1KDM4E | |
| SCHEMBL6078272 | 0.84 | L3MBTL1 (0.53) | DRD2HTR2AALDH1A1KDM4ETSHR | |
| SCHEMBL6076788 | 0.80 | LIPG (0.39) | KMT2AMEN1KCNH2ALDH1A1ALOX15 | |
| SCHEMBL6077393 | 0.79 | LIPG (0.39) | KCNH2DRD2SIGMAR1ALDH1A1KDM4E | |
| SCHEMBL6078249 | 0.79 | PARP1 (0.45) | KMT2ADRD2ALDH1A1DRD3 | |
| SCHEMBL6077535 | 0.76 | LIPG (0.51) | KMT2AALDH1A1KDM4EALOX15HSD17B10 | |
| SCHEMBL14366509 | 0.75 | KMT2A (0.71) | KMT2AMEN1KCNH2KCNA5DRD2 | |
| SCHEMBL7634958 | 0.75 | KMT2A (0.71) | KMT2AMEN1KCNH2KCNA5DRD2 | |
| SCHEMBL6078320 | 0.75 | LIPG (0.38) | SIGMAR1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109186-B2 | 4-hydroxy-5-oxo-1-(2-[4-methylpiperazin-1-yl]ethyl)-2,5-dihydro-1H-pyrrole-3-carboxylic acid (3,4-dichlorobenzyl)-methyl-amide for human immunodeficiency virus (HIV) treatment | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-09-19 | — | — | US | disclosed |
| US-20040110804-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110804-A1 | HIV integrase inhibitors | CDKN1A, SAMHD1, CTCF | KMT2A 736/4885MEN1 4784/4885KCNH2 4138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.